Ionis EVP sells 362 shares in planned trade

IONIS PHARMACEUTICALS INC EVP and Chief Development Officer Holly B. Kordasiewicz sold 362 shares of common stock in an open-market transaction at $84.30 per share on July 7, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC EVP and Chief Development Officer Holly B. Kordasiewicz sold 362 shares of common stock in an open-market transaction at $84.30 per share on July 7, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, and she now holds 22,096 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 362 shares

Net Sell 1 txn

Insider Kordasiewicz Holly B.

Role EVP, Chief Development Officer

Sold 362 shs ($31K)

Type	Security	Shares	Price	Value
Sale	Common Stock	362	$84.30	$31K

Holdings After Transaction: Common Stock — 22,096 shares (Direct)

Footnotes (1)

F1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026

Key Figures

Shares sold: 362 shares Sale price: $84.30 per share Shares owned after transaction: 22,096 shares

3 metrics

Shares sold 362 shares Open-market sale on July 7, 2026

Sale price $84.30 per share Common Stock transaction

Shares owned after transaction 22,096 shares Direct ownership following sale

Key Terms

Rule 10b5-1 Trading Plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 Trading Plan regulatory

"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action is described as an open-market sale of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"The security title for the reported transaction is Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ionis (IONS) report for Holly B. Kordasiewicz?

Ionis reported that EVP Holly B. Kordasiewicz sold 362 common shares. The transaction was an open-market sale at $84.30 per share, completed on July 7, 2026, and categorized as a routine disposition rather than a large ownership change.

How many Ionis (IONS) shares does Holly B. Kordasiewicz hold after the sale?

After the reported sale, Holly B. Kordasiewicz holds 22,096 Ionis shares directly. This figure reflects her position following the 362-share open-market transaction and helps indicate that the sale represents a relatively small portion of her overall ownership stake.

At what price were the Ionis (IONS) shares sold in this Form 4 filing?

The 362 Ionis shares were sold at an average price of $84.30 per share. This price comes from the Form 4 disclosure describing the transaction as an open-market or private sale, providing investors with the per-share value for the reported disposition.

Was the Ionis (IONS) insider sale made under a Rule 10b5-1 trading plan?

Yes, the insider sale was made under a Rule 10b5-1 trading plan. A footnote explains the shares were sold pursuant to a trading plan adopted by Holly B. Kordasiewicz on March 13, 2026, indicating the transaction was pre-arranged rather than opportunistic.

Who is Holly B. Kordasiewicz in relation to Ionis (IONS)?

Holly B. Kordasiewicz serves as EVP and Chief Development Officer at Ionis. Her role is disclosed in the Form 4, which identifies her as an executive officer rather than a director or 10% owner, providing context for the scale and significance of her reported share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/09/2026 - 06:07 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kordasiewicz Holly B.

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

CALIFORNIA

92010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/07/2026		S		362⁽¹⁾	D	$84.3	22,096	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026

	By: Patrick R. O'Neil, attorney-in-fact For: Holly B. Kordasiewicz	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR